Reaction Details |
| Report a problem with these data |
Target | Adenosine receptor A1 |
---|
Ligand | BDBM26250 |
---|
Substrate/Competitor | BDBM21173 |
---|
Meas. Tech. | Receptor Binding Assay |
---|
Ki | 7.2±n/a nM |
---|
Citation | Zhang, X; Tellew, JE; Luo, Z; Moorjani, M; Lin, E; Lanier, MC; Chen, Y; Williams, JP; Saunders, J; Lechner, SM; Markison, S; Joswig, T; Petroski, R; Piercey, J; Kargo, W; Malany, S; Santos, M; Gross, RS; Wen, J; Jalali, K; O'Brien, Z; Stotz, CE; Crespo, MI; Diaz, JL; Slee, DH Lead Optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A Adenosine Receptor Antagonists for the Treatment of Parkinson's Disease. J Med Chem51:7099-7110 (2008) [PubMed] Article |
---|
More Info.: | Get all data from this article, Solution Info, Assay Method |
---|
|
Adenosine receptor A1 |
---|
Name: | Adenosine receptor A1 |
Synonyms: | A1 adenosine receptor (hA1) | A1AR | AA1R_HUMAN | ADENOSINE A1 | ADORA1 | Adenosine A1 receptor (A1AR) | Adenosine A1-receptor | Adenosine receptor A1 (A1) | Adenosine receptor A1 (hA1) | Adenosine transporter (AdT) |
Type: | G Protein-Coupled Receptor (GPCR) |
Mol. Mass.: | 36520.92 |
Organism: | Homo sapiens (Human) |
Description: | P30542 |
Residue: | 326 |
Sequence: | MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGA
LVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVT
PRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYM
VYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALIL
FLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFL
KIWNDHFRCQPAPPIDEDLPEERPDD
|
|
|
BDBM26250 |
---|
BDBM21173 |
---|
Name | BDBM26250 |
Synonyms: | N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-[6-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidin-4-yl]acetamide | pyrazolylpyrimidine derivative, 16d |
Type | Small organic molecule |
Emp. Form. | C20H23N7O |
Mol. Mass. | 377.4429 |
SMILES | CC(=O)Nc1cc(nc(n1)-n1nc(C)cc1C)-c1cccc(n1)N1CCCC1 |
Structure |
|